178 related articles for article (PubMed ID: 26980109)
1. 2,4,6-Triaminopyrimidine as a Novel Hinge Binder in a Series of PI3Kδ Selective Inhibitors.
Patel L; Chandrasekhar J; Evarts J; Haran AC; Ip C; Kaplan JA; Kim M; Koditek D; Lad L; Lepist EI; McGrath ME; Novikov N; Perreault S; Puri KD; Somoza JR; Steiner BH; Stevens KL; Therrien J; Treiberg J; Villaseñor AG; Yeung A; Phillips G
J Med Chem; 2016 Apr; 59(7):3532-48. PubMed ID: 26980109
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors.
Ma CC; Zhang CM; Tang LQ; Liu ZP
Eur J Med Chem; 2018 May; 151():9-17. PubMed ID: 29601991
[TBL] [Abstract][Full Text] [Related]
3. Discovery, Optimization, and Evaluation of Quinazolinone Derivatives with Novel Linkers as Orally Efficacious Phosphoinositide-3-Kinase Delta Inhibitors for Treatment of Inflammatory Diseases.
Liu K; Li D; Zheng W; Shi M; Chen Y; Tang M; Yang T; Zhao M; Deng D; Zhang C; Liu J; Yuan X; Yang Z; Chen L
J Med Chem; 2021 Jul; 64(13):8951-8970. PubMed ID: 34138567
[TBL] [Abstract][Full Text] [Related]
4. SAR study of 5-alkynyl substituted quinazolin-4(3H)-ones as phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
Wei M; Zhang X; Wang X; Song Z; Ding J; Meng LH; Zhang A
Eur J Med Chem; 2017 Jan; 125():1156-1171. PubMed ID: 27846451
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of WO2014075392 and WO2014075393, Merck's first PI3Kδ inhibitor filings.
Norman P
Expert Opin Ther Pat; 2014 Nov; 24(11):1277-82. PubMed ID: 25326077
[TBL] [Abstract][Full Text] [Related]
6. Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
Xin M; Duan W; Feng Y; Hei YY; Zhang H; Shen Y; Zhao HY; Mao S; Zhang SQ
Bioorg Med Chem; 2018 May; 26(8):2028-2040. PubMed ID: 29534936
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and optimization of furano[3,2-d]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors.
Hoemann M; Wilson N; Argiriadi M; Banach D; Burchat A; Calderwood D; Clapham B; Cox P; Duignan DB; Konopacki D; Somal G; Vasudevan A
Bioorg Med Chem Lett; 2016 Nov; 26(22):5562-5567. PubMed ID: 27789138
[TBL] [Abstract][Full Text] [Related]
8. Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and autoimmune disease.
Cushing TD; Hao X; Shin Y; Andrews K; Brown M; Cardozo M; Chen Y; Duquette J; Fisher B; Gonzalez-Lopez de Turiso F; He X; Henne KR; Hu YL; Hungate R; Johnson MG; Kelly RC; Lucas B; McCarter JD; McGee LR; Medina JC; San Miguel T; Mohn D; Pattaropong V; Pettus LH; Reichelt A; Rzasa RM; Seganish J; Tasker AS; Wahl RC; Wannberg S; Whittington DA; Whoriskey J; Yu G; Zalameda L; Zhang D; Metz DP
J Med Chem; 2015 Jan; 58(1):480-511. PubMed ID: 25469863
[TBL] [Abstract][Full Text] [Related]
9. Effects of AS2541019, a novel selective PI3Kδ inhibitor, on antibody production and hamster to rat xenotransplantation.
Marui T; Fukahori H; Kawashima T; Ito M; Akamatsu M; Kaneko Y; Takahashi F; Imada S; Morokata T
Eur J Pharmacol; 2018 May; 826():179-186. PubMed ID: 29518396
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Evaluation of Novel 2H-Benzo[e]-[1,2,4]thiadiazine 1,1-Dioxide Derivatives as PI3Kδ Inhibitors.
Gong YP; Tang LQ; Liu TS; Liu ZP
Molecules; 2019 Nov; 24(23):. PubMed ID: 31775363
[TBL] [Abstract][Full Text] [Related]
11. Discovery and optimization of heteroaryl piperazines as potent and selective PI3Kδ inhibitors.
Zhou H; McGowan MA; Lipford K; Christopher M; Fradera X; Witter D; Lesburg CA; Li C; Methot JL; Lampe J; Achab A; Shaffer L; Goldenblatt P; Shah S; Bass A; Schroeder G; Chen D; Zeng H; Augustin MA; Katz JD
Bioorg Med Chem Lett; 2020 Jan; 30(1):126715. PubMed ID: 31757666
[TBL] [Abstract][Full Text] [Related]
12. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.
Liang X; Li F; Chen C; Jiang Z; Wang A; Liu X; Ge J; Hu Z; Yu K; Wang W; Zou F; Liu Q; Wang B; Wang L; Zhang S; Wang Y; Liu Q; Liu J
Eur J Med Chem; 2018 Aug; 156():831-846. PubMed ID: 30053721
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of PI3Kδ reduces kidney infiltration by macrophages and ameliorates systemic lupus in the mouse.
Suárez-Fueyo A; Rojas JM; Cariaga AE; García E; Steiner BH; Barber DF; Puri KD; Carrera AC
J Immunol; 2014 Jul; 193(2):544-54. PubMed ID: 24935930
[TBL] [Abstract][Full Text] [Related]
14. The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.
Coffey G; Betz A; DeGuzman F; Pak Y; Inagaki M; Baker DC; Hollenbach SJ; Pandey A; Sinha U
J Pharmacol Exp Ther; 2014 Dec; 351(3):538-48. PubMed ID: 25253883
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and SAR study of potent and selective PI3Kδ inhibitors.
Bui M; Hao X; Shin Y; Cardozo M; He X; Henne K; Suchomel J; McCarter J; McGee LR; San Miguel T; Medina JC; Mohn D; Tran T; Wannberg S; Wong J; Wong S; Zalameda L; Metz D; Cushing TD
Bioorg Med Chem Lett; 2015 Mar; 25(5):1104-9. PubMed ID: 25666823
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of WO2013116562A, an orally active PI3Kδ inhibitor for the treatment of asthma.
Norman P
Expert Opin Ther Pat; 2014 May; 24(5):603-7. PubMed ID: 24387136
[TBL] [Abstract][Full Text] [Related]
17. Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.
Jia H; Dai G; Su W; Xiao K; Weng J; Zhang Z; Wang Q; Yuan T; Shi F; Zhang Z; Chen W; Sai Y; Wang J; Li X; Cai Y; Yu J; Ren P; Venable J; Rao T; Edwards JP; Bembenek SD
J Med Chem; 2019 May; 62(10):4936-4948. PubMed ID: 31033293
[TBL] [Abstract][Full Text] [Related]
18. Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kδ inhibitors.
Terstiege I; Perry M; Petersen J; Tyrchan C; Svensson T; Lindmark H; Öster L
Bioorg Med Chem Lett; 2017 Feb; 27(3):679-687. PubMed ID: 28017532
[TBL] [Abstract][Full Text] [Related]
19. Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
Liu K; Zheng W; Chen Y; Tang M; Li D; Deng D; Yang T; Zhang C; Liu J; Yuan X; Shi M; Li X; Guo Y; Zhou Y; Zhao M; Chen L
J Med Chem; 2022 Jul; 65(14):9893-9917. PubMed ID: 35831917
[TBL] [Abstract][Full Text] [Related]
20. Discovery and profiling of a selective and efficacious Syk inhibitor.
Thoma G; Smith AB; van Eis MJ; Vangrevelinghe E; Blanz J; Aichholz R; Littlewood-Evans A; Lee CC; Liu H; Zerwes HG
J Med Chem; 2015 Feb; 58(4):1950-63. PubMed ID: 25633741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]